Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2025

Summary

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

According to APO Research, The global Amyotrophic Lateral Sclerosis (ALS) Treatment market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Amyotrophic Lateral Sclerosis (ALS) Treatment include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma and Lunan Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Company

Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole
Edaravone (Radicava)
Other
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital
Drugs Store
Other
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital
Drugs Store
Other
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Riluzole
2.2.3 Edaravone (Radicava)
2.2.4 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Drugs Store
2.3.4 Other
2.4 Assumptions and Limitations
3 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Type
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2026-2031)
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2020-2025)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2020-2031)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2020-2025)
5.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2026-2031)
5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
5.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
5.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
5.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
5.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
6.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2020-2025)
6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2020-2025)
6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Head Office and Area Served
6.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application
6.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturers Established Date
6.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
9.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
10.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
10.4 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
11.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Mitsubishi Tanabe Pharma
12.1.1 Mitsubishi Tanabe Pharma Company Information
12.1.2 Mitsubishi Tanabe Pharma Business Overview
12.1.3 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.1.5 Mitsubishi Tanabe Pharma Recent Developments
12.2 Sanofi
12.2.1 Sanofi Company Information
12.2.2 Sanofi Business Overview
12.2.3 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.2.5 Sanofi Recent Developments
12.3 Mylan Pharma
12.3.1 Mylan Pharma Company Information
12.3.2 Mylan Pharma Business Overview
12.3.3 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.3.5 Mylan Pharma Recent Developments
12.4 Apotex
12.4.1 Apotex Company Information
12.4.2 Apotex Business Overview
12.4.3 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.4.5 Apotex Recent Developments
12.5 Glemark Generics
12.5.1 Glemark Generics Company Information
12.5.2 Glemark Generics Business Overview
12.5.3 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.5.5 Glemark Generics Recent Developments
12.6 Covis Pharma
12.6.1 Covis Pharma Company Information
12.6.2 Covis Pharma Business Overview
12.6.3 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.6.5 Covis Pharma Recent Developments
12.7 Sun Pharma
12.7.1 Sun Pharma Company Information
12.7.2 Sun Pharma Business Overview
12.7.3 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.7.5 Sun Pharma Recent Developments
12.8 Lunan Pharma
12.8.1 Lunan Pharma Company Information
12.8.2 Lunan Pharma Business Overview
12.8.3 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
12.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
12.8.5 Lunan Pharma Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings